Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) shares traded down 7.2% on Thursday . The stock traded as low as $3.95 and last traded at $3.99. 872,800 shares were traded during mid-day trading, a decline of 24% from the average session volume of 1,150,810 shares. The stock had previously closed at $4.30.
Several research analysts have weighed in on the company. ValuEngine upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 4th. Gabelli upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 29th. BMO Capital Markets restated a “market perform” rating and issued a $3.00 price target (up from $2.75) on shares of Tetraphase Pharmaceuticals in a research note on Thursday, March 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, March 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and an average target price of $7.22.
The stock has a market cap of $219.28 million, a P/E ratio of -1.52 and a beta of 2.64.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. The firm had revenue of $1.89 million during the quarter, compared to the consensus estimate of $1.88 million. Tetraphase Pharmaceuticals had a negative return on equity of 85.70% and a negative net margin of 1,061.06%. analysts predict that Tetraphase Pharmaceuticals Inc. will post -1.56 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Paloma Partners Management Co bought a new position in shares of Tetraphase Pharmaceuticals during the 4th quarter valued at approximately $210,000. Virtus Fund Advisers LLC purchased a new stake in Tetraphase Pharmaceuticals during the 4th quarter valued at $376,000. Two Sigma Investments LP raised its holdings in Tetraphase Pharmaceuticals by 276.7% during the 4th quarter. Two Sigma Investments LP now owns 64,413 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 47,313 shares during the period. Dynamic Technology Lab Private Ltd raised its holdings in Tetraphase Pharmaceuticals by 322.1% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 58,079 shares during the period. Finally, Alambic Investment Management L.P. purchased a new stake in Tetraphase Pharmaceuticals during the 1st quarter valued at $356,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.